Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia

Blood Cancer Journal

Volumn 4, Issue 8, 2014, Pages

  Cummins, K D ^a   Jane, S M ^a   Nikovic, S ^b   Bazargan, A ^b   Filshie, R ^b   Sutrave, G ^c   Hertzberg, M ^c   Scott, A ^d   Lane, S ^d   Yannakou, C K ^e   Ritchie, D ^e   D'Rozario, J ^f   Black, J ^g   Bavishi, K ^g   Wei, A ^a  

^a MONASH UNIVERSITY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f CANBERRA HOSPITAL   (Australia)

^g Queensland Department of Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CYTARABINE; ETOPOSIDE; FLT3 LIGAND; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; MELPHALAN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CHEMOTHERAPY; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG POTENCY; HUMAN; LETTER; LEUKEMIA RELAPSE; MIDDLE AGED; OUTCOME ASSESSMENT; SALVAGE THERAPY;

EID: 84906854162     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.59     Document Type: Letter

References (5)

1. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.p
2. Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood 2004; 104: 1145-1150.p
3. Taylor SJ, Dagger SA, Thien CB, Wikstrom ME, Langdon WY. Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling. Blood 2012; 120: 4049-4057.p
4. Pratz K, Cho E, Levis M, Karp J, Gore S, McDevitt M et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010; 24: 1437-1444.p
5. Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P et al. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. Leuk Lymphoma 2013; 54: 336-341.p